Chronic inflammation

Based on the provided sources, chronic inflammation is intricately linked to several age-related pathological conditions, notably cardiovascular disease, metabolic dysregulation, and immunosenescence. The consensus across clinical and experimental literature indicates that inflammatory pathways play a causal role in the progression of atherothrombosis [6], as demonstrated by trials targeting interleukin-1β to reduce cardiovascular risk independently of lipid levels [6], as well as the predictive value of inflammatory biomarkers like high-sensitivity C-reactive protein in vascular events [7]. Furthermore, chronic low-grade inflammation intersects with metabolic syndrome [2], age-related skeletal muscle alterations [10], and the broader framework of "inflammaging(definition)" tied to oxidative stress and immunosenescence [9].

Despite these clinical associations, open questions remain regarding the precise mechanistic drivers that transition acute immune responses into pathological chronic inflammation during aging. Specifically, the precise geroscience intersections between redox signaling fidelity, immunosenescence, and tissue-specific inflammatory loops—such as those investigated in skeletal muscle decline [10] or neurodegenerative frameworks [4]—require further elucidation to design targeted interventions.

The strength of evidence varies depending on the domain. It is exceptionally strong for the inflammatory hypothesis of cardiovascular disease, supported by large-scale randomized trials demonstrating that anti-inflammatory and statin therapies modify vascular risk via inflammatory pathways [6, 7]. Conversely, evidence concerning specific therapeutic interventions for broader age-related inflammatory states, such as exercise modulation of muscle inflammation in elderly cohorts [10] or the precise management of inflammaging(definition) and redox signaling [9], is still evolving and necessitates further clinical validation.